Gentronix Blue Screen HC Genotoxicity Screening Test Now Available from Charles Rivers Laboratories

Charles River Laboratories now offers Gentronix BlueScreen HC Screening services for the early detection of genotoxicity. This new initiative provides customers of Charles River with the high-accuracy, low-compound use and rapid results generation required to identify genotoxic problem compounds earlier in discovery and preclinical development, thereby reducing later stage attrition and increasing the number of candidates progressing into development and the clinic.

BlueScreen HC uses Gaussia luciferase to detect the up-regulation of a key reporter gene, GADD-45a, in response to genotoxic stress and can detect all known classes of genotoxins. In addition, Charles River will also offer BlueScreen HC with metabolic activation for the detection of pro-genotoxins, providing valuable additional information for clients.

Dr. Brian Bathgate, Senior Vice President, Global Preclinical Services at Charles River, commented, “Charles River is committed to providing exceptional, leading-edge services to our customers in order to help them reduce attrition and increase efficiency in their drug development programs. The introduction of BlueScreen HC will allow Charles River’s customers to access an innovative new technology to assist them with the discovery and development of new drug compounds faster and more cost effectively.”

Dr. Steve Beasley, Commercial Director at Gentronix, added, “We have been impressed with the technical excellence of the Charles River team and the diligence with which they have validated their BlueScreen HC testing operations. Charles River is well-positioned as an industry leader to bring these new technologies to customers across a wide range of sectors.”